natgillin/translations-raw huggingface dataset:
≥100,000 copies/ml
≥100 000 kopija/ml
Subjects with at least one functional CYP2C19 allele.
Osobe s najmanje jednim funkcionalnim CYP2C19 alelom.
Systemic exposure to atazanavir at doses that resulted in maternal toxicity was at least equal to or slightly greater than that observed in humans given 400 mg once daily.
Sistemska izloženost atazanaviru u dozama koje su rezultirale maternalnom toksičnošću bila je barem jednaka ili nešto veća od one opažene u ljudi koji su dobivali 400 mg jedanput na dan.
• buprenorphine (used to treat opioid addiction and pain).
• buprenorfin (primijenjuje se za liječenje ovisnosti o opijatima i boli)
In long-term carcinogenicity studies of atazanavir in mice and rats, an increased incidence of benign hepatic adenomas was seen in female mice only.
U dugotrajnim ispitivanjima kancerogenosti atazanavira u miševa i štakora opažena je povećana učestalost benignih adenoma jetre, ali samo u ženki miša.
** When compared to rifabutin 150 mg once daily alone.
** Kad se usporedio samo s rifabutinom 150 mg jedanput na dan.
A safe and effective dose in combination with atazanavir has not been established for sildenafil when used to treat pulmonary arterial hypertension.
Nije ustanovljena sigurna i djelotvorna doza sidenafila u kombinaciji s atazanavirom kad se sildenafil primjenjuje za liječenje plućne arterijske hipertenzije.
If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.
Ako se u tih bolesnika dokaže pogoršanje bolesti jetre, mora se razmotriti privremeni ili trajni prekid liječenja.
In a multiple-dose study in HIV-infected patients dosed with 400 mg of atazanavir once daily with a light meal for 12 weeks, atazanavir was detected in the cerebrospinal fluid and semen.
U ispitivanju višestrukih doza u bolesnika zaraženih HIVom koji su primali doze od 400 mg atazanavira jedanput na dan uz lagani obrok tijekom 12 tjedana, atazanavir je otkriven u cerebrospinalnom likvoru i sjemenu.
• Atazanavir may affect how well your kidneys work.
• Atazanavir može utjecati na to kako dobro rade vaši bubrezi.
50 to <100 cells/mm
50 do <100 stanica /mm
While the concentration of ethinyloestradiol was increased with atazanavir given alone, due to both UGT and CYP3A4 inhibition by atazanavir, the net effect of atazanavir/ritonavir is a decrease in ethinyloestradiol levels because of the inducing effect of ritonavir.
Iako je koncentracija etinilestradiola bila povišena kad se atazanavir davao sam, zbog toga što atazanavir inhibira enzime UGT i CYP3A4, neto učinak atazanavira/ritonavira je sniženje razina etinilestradiola zbog inducirajućeg učinka ritonavira.
• Liver problems may uncommonly happen.
• Manje često se mogu pojavit problemi s jetrom.
ANTIMYCOBACTERIAL
ANTIMIKOBAKTERIJSKI
There are other medicines that may not mix with Atazanavir Mylan.
Postoje i drugi lijekovi koji se ne smiju miješati s lijekom Atazanavir Mylan.
In paediatric patients with pre-existing conduction problems (second degree or higher atrioventricular or complex bundle-branch block), Atazanavir Mylan should be used with caution and only if the benefits exceed the risk.
U pedijatrijskih bolesnika s već prisutnim poremećajem provođenja (atrioventrikularni blok drugog ili višeg stupnja ili kompletni blok grane) Atazanavir Mylan treba primjenjivati s oprezom i samo ako je korist veća od rizika.
Fifteen of 120 (13%) patients in the atazanavir + ritonavir treatment arm and 17 of 123 (14%) patients in the lopinavir + ritonavir arm had four or more of the PI substitutions L10, M46, I54, V82, I84, and L90.
Petnaest od 120 (13%) bolesnika u terapijskoj skupini koja je primala atazanavir + ritonavir i 17 od 123 (14%) bolesnika u skupini koja je primala lopinavir + ritonavir imalo je četiri ili više supstitucija za rezistenciju na inhibitore proteaze: L10, M46, I54, V82, I84 i L90.
In antiretroviral treatment experienced patients from Studies 009, 043, and 045, 100 isolates from patients designated as virological failures on therapy that included either atazanavir, atazanavir + ritonavir, or atazanavir + saquinavir were determined to have developed resistance to atazanavir.
U antiretrovirusnom liječenju prethodno liječenih bolesnika u Ispitivanjima 009, 043 i 045, u 100 izolata iz bolesnika u kojih je terapija atazanavirom, atazanavirom s ritonavirom ili atazanavirom sa sakvinavirom bila virološki neuspješna utvrđeno je da se razvila rezistencija na atazanavir.
Some medicines may interact with ritonavir, a medicine that is taken with Atazanavir Mylan.
Neki lijekovi mogu ući u interakciju s ritonavirom, koji se uzima zajedno s lijekom Atazanavir Mylan.
Atazanavir Mylan is not a cure for HIV infection.
Atazanavir Mylan neće izliječiti HIV-infekciju.
Medicinal products by therapeutic area
Lijekovi prema terapijskom području
(ritonavir 100 mg capsules twice daily)
(ritonavir 100 mg kapsule dvaput na dan)
There were no reported cases of kernicterus in neonates.
Nije bilo zabilježenih slučajeva kernikterusa u novorođenčadi.
Reduced plasma concentrations of atazanavir may be the consequence of increased gastric pH if antacids, including buffered medicinal products, are administered with atazanavir.
Snižene koncentracije atazanavira u plazmi mogu biti posljedica povišenog želučanog pH ako se antacidi, uključujući puferirane lijekove, primjenjuju s atazanavirom.
INHALED BETA AGONISTS Salmeterol
INHALACIJSKI BETA AGONISTI
For bottles: Once opened, use within 90 days.
Za boce: Nakon otvaranja iskoristiti u roku od 90 dana.
Administration of atazanavir with ritonavir with either a light or a high-fat meal decreased the coefficient of variation of AUC and Cmax by approximately 25% compared to the fasting state.
Primjena atazanavira s ritonavirom uz lagani obrok ili obrok bogat mastima smanjila je koeficijent varijacije AUC i Cmax za približno 25% u usporedbi s onima natašte.
The efficacy of atazanavir/ritonavir in combination with tenofovir disoproxil fumarate in treatment-experienced patients has been demonstrated in clinical study 045 and in treatment naive patients in clinical study 138 (see sections 4.8 and 5.1).
Djelotvornost atazanavira s ritonavirom u kombinaciji s tenofovirdizoproksilfumaratom u prethodno liječenih bolesnika dokazana je u kliničkom ispitivanju 045, a u bolesnika koji prethodno nisu bili liječeni u kliničkom ispitivanju 138 (vidjeti dijelove 4.8 i 5.1).
Integrase Inhibitors Raltegravir 400 mg twice daily
Inhibitori integraze Raltegravir 400 mg dvaput na dan
The safety and efficacy of atazanavir has not been established in patients with significant underlying liver disorders.
Sigurnost i djelotvornost atazanavira nije ustanovljena u bolesnika sa značajnom osnovnom bolešću jetre.
Children
Djeca
Efficacy Atazanavir/ritonavir is not effective in viral strains harbouring multiple mutations of resistance.
Kombinacija atazanavir/ritonavir nije djelotvorna kod sojeva virusa koji nose višestruke mutacije za rezistenciju.
Combination of the PDE5 inhibitor sildenafil when used for the treatment of pulmonary arterial hypertension (PAH) only (see section 4.5).
Kombinacija s inhibitorom PDE5, sildenafilom, samo kad se primjenjuje za liječenje plućne arterijske hipertenzije (PAH) (vidjeti dio 4.5).
No significant effect on lamivudine and zidovudine concentrations was observed.
Nije opažen značajni učinak na koncentracije lamivudina i zidovudina.
Per protocol analysis e
Analiza prema protokolue
Atazanavir is an azapeptide HIV-1 protease inhibitor (PI).
Atazanavir je azapeptidni inhibitor proteaze virusa HIV-1.
If you notice any symptoms of infection, please inform your doctor immediately.
Ako primijetite ikakve znakove infekcije, odmah o tome obavijestite svog liječnika.
Stevens-Johnson syndrome (SJS), erythema multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported with the use of atazanavir (see section 4.4).
Stevens-Johnsonov sindrom (SJS), multiformni eritem, toksične kožne erupcije i medikamentozni osip s eozinofilijom i sistemskim simptomima (DRESS) zabilježeni su kod primjene atazanavira (vidjeti dio 4.4).
uncommon: depression, disorientation, anxiety, insomnia, sleep disorder, abnormal dream
manje često: depresija, dezorijentacija, anksioznost, nesanica, poremećaj spavanja, abnormalni snovi
The potential for PR prolongation should be considered in cases of overdose (see section 4.9).
U slučajevima predoziranja treba uzeti u obzir mogućnost produljenja PR intervala (vidjeti dio 4.9).
The primary endpoint was the time-averaged difference in change from baseline in HIV RNA through 48 weeks (Table 6).
Primarni ishod bila je vremenski uprosječena razlika između početne vrijednosti HIV RNK i vrijednosti u 48. tjednu (tablica 6).
• weight decreased, weight gain, anorexia (loss of appetite), appetite increased
• smanjenje tjelesne težine, povećanje tjelesne težine, anoreksija (gubitak apetita), pojačan apetit
Itraconazole, like ketoconazole, is a potent inhibitor as well as a substrate of CYP3A4.
Itrakonazol, kao i ketokonazol, jaki je inhibitor kao i supstrat enzima CYP3A4.
Patients should be closely monitored for tenofovir disoproxil fumarate-associated adverse reactions, including renal disorders.
Bolesnike treba pažljivo nadzirati zbog nuspojava tenofovirdizoproksilfumarata, uključujući poremećaje bubrega.
Table 8: Steady-State Pharmacokinetics of Atazanavir with ritonavir in HIV-Infected Pregnant Women in the Fed State atazanavir 300 mg with ritonavir 100 mg
Tablica 8: Farmakokinetika atazanavira s ritonavirom u stanju dinamičke ravnoteže u trudnica zaraženih HIV-om u sitom stanju atazanavir 300 mg s ritonavirom 100 mg
• gynaecomastia (breast enlargement in men)
• ginekomastija (povećanje grudi u muškaraca)
If you notice any of these symptoms please inform your doctor.
Ako primijetite neki od ovih simptoma, obavijestite o tome svog liječnika.
Atazanavir plasma trough concentrations were approximately 2-fold higher during the postpartum period when compared to those observed historically in HIV infected non-pregnant patients.
Najniže koncentracije atazanavira u plazmi bile su približno dvostruko više tijekom postpartalnog razdoblja u usporedbi s onima prethodno opaženima u bolesnica zaraženih HIV-om koje nisu bile trudne.
Rifabutin 150 mg twice weekly
Rifabutin 150 mg dvaput tjedno
- The other ingredients are lactose monohydrate, crospovidone, magnesium stearate.
Drugi su sastojci laktoza hidrat, krospovidon, magnezijev stearat.
Atazanavir (without ritonavir) has been studied in adult patients with severe renal impairment (n=20), including those on haemodialysis, at multiple doses of 400 mg once daily.
Atazanavir (bez ritonavira) ispitan je u odraslih bolesnika s teškim oštećenjem funkcije bubrega (n=20), uključujući one na hemodijalizi, pomoću višestrukih doza od 400 mg jedanput na dan.
What Atazanavir Mylan looks like and contents of the pack
Kako Atazanavir Mylan izgleda i sadržaj pakiranja
Eleven subjects (13%) in the unboosted atazanavir group and 6 (7%) in the atazanavir + ritonavir group, had virologic rebound.
U jedanaest ispitanika (13%) u skupini liječenoj nepojačanim atazanavirom i 6 (7%) ispitanika u skupini koja je primala atazanavir + ritonavir virusno je opterećenje ponovno postalo mjerljivo.
If you develop a rash inform your doctor immediately.
Ako razvijete osip, odmah o tome obavijestite svog liječnika.
The risk of myopathy including rhabdomyolysis may also be increased with atorvastatin, which is also metabolised by CYP3A4.
Rizik od miopatije, uključujući rabdomiolizu, također može biti povećan s primjenom atorvastatina, koji također metabolizira enzim CYP3A4.
This decrease in atazanavir exposure might negatively impact the efficacy of atazanavir.
Ovo smanjenje izloženosti atazanaviru može negativno utjecati na djelotvornost atazanavira.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products (see section 4.8).
U slučaju istovremene antivirusne terapije zbog hepatitisa B ili C treba provjeriti odgovarajuće Sažetke opisa svojstava lijeka za te lijekove (vidjeti dio
Regular monitoring of the renal function of patients should be maintained throughout the treatment duration (see section 4.4).
Redovito praćenje bubrežnih funkcija u bolesnika treba se održavati tijekom cijelog trajanja liječenja (pogledajte dio 4.4).
2nd Trimester (n=9)
2. tromjesečje (n=9)
The most frequently reported laboratory abnormality in patients receiving regimens containing atazanavir and one or more NRTIs was elevated total bilirubin reported predominantly as elevated indirect [unconjugated] bilirubin (87% Grade 1, 2, 3, or 4).
Najčešće zabilježeni laboratorijski nalaz u bolesnika koji primaju terapiju atazanavirom i jednim ili više NRTI-jeva bio je povišen ukupni bilirubin zabilježen pretežno kao povišeni indirektni [nekonjugirani] bilirubin (87% 1., 2., 3. ili 4. stupnja).
Ethinyloestradiol 35 µg + norethindrone
Etinilestradiol 35 μg + noretindron
The dose of Atazanavir Mylan capsules for children is calculated by body weight and is taken once daily with food and 100 mg ritonavir as shown below:
Doza Atazanavir Mylan kapsula za djecu izračunava se na temelju tjelesne težine i uzima se jedanput na dan s hranom i 100 mg ritonavira na sljedeći način:
Clarithromycin Cmax ↑50% (↑32%
Klaritromicin Cmax ↑50% (↑32%
Co-administration of atazanavir with ritonavir at doses greater than 100 mg once daily has not been clinically evaluated.
Istovremena primjena atazanavira s ritonavirom u dozama višima od 100 mg jedanput na dan nije klinički procijenjena.
• if you are taking any of these medicines: see also Other medicines and Atazanavir Mylan - rifampicin, an antibiotic used to treat tuberculosis - astemizole or terfenadine (commonly used to treat allergy symptoms, these medicines may be available without prescription); cisapride (used to treat gastric reflux, sometimes called heartburn); pimozide (used to treat schizophrenia); quinidine or bepridil (used to correct heart rhythm); ergotamine, dihydroergotamine, ergonovine, methylergonovine (used to treat headaches); and alfuzosin (used to treat enlarged prostatic gland).
• ako uzimate neki od ovih lijekova: vidjeti također Drugi lijekovi i Atazanavir Mylan - rifampicin, antibiotik za liječenje tuberkuloze - astemizol ili terfenadin (obično se primjenjuju za liječenje simptoma alergije i mogu se nabaviti bez recepta); cisaprid (primjenjuje se za liječenje želučanog refluksa, tj. žgaravice); pimozid (primjenjuje se za liječenje shizofrenije); kinidin ili bepridil (primjenjuju se za liječenje poremećaja srčanog ritma); ergotamin, dihidroergotamin, ergonovin, metilergonovin (primjenjuju se za liječenje glavobolje); i alfuzosin (primjenjuje se za liječenje povećanja prostate)
Of importance, many studies were conducted with unboosted atazanavir, which is not the recommended regimen of atazanavir (see section 4.4).
Važno je istaknuti da su mnoga ispitivanja provedena s nepojačanim atazanavirom, što nije preporučen oblik liječenja atazanavirom (vidjeti dio 4.4).
Age/gender
Dob/Spol
Contains lactose See leaflet for further information.
Sadrži laktozu Vidjeti uputu o lijeku za dodatne informacije.
Therefore, postpartum patients should be closely monitored for adverse reactions.
Stoga, bolesnice u postpartalnom razdoblju treba pažljivo pratiti zbog nuspojava.
Subjects without a functional CYP2C19 allele.
Osobe bez funkcionalnog CYP2C19 alela.
The absorption of atazanavir may be reduced in situations where gastric pH is increased irrespective of cause.
Apsorpcija atazanavira može biti smanjena kad je povišen želučani pH, bez obzira na uzrok.
In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
U bolesnika zaraženih HIV-om s teškom imunodeficijencijom u vrijeme uvođenja kombinirane antiretrovirusne terapije (CART) može doći do upalne reakcije na asimptomatske ili rezidualne oportunističke patogene, što može prouzročiti ozbiljno kliničko stanje ili pogoršanje simptoma.
There were no cases of lactic acidosis observed in the clinical trial AI424-182.
U kliničkom ispitivanju AI424-182 nije opažen niti jedan slučaj laktacidoze.
In case of withdrawal of ritonavir from the initial recommended ritonavir boosted regimen (see section 4.4), unboosted atazanavir could be maintained in patients with mild hepatic impairment at a dose of 400 mg and in patients with moderate hepatic impairment with a reduced dose of 300 mg once daily with food (see section 5.2).
U slučaju izostavljanja ritonavira iz početnog preporučenog režima pojačanog ritonavirom (vidjeti dio 4.4), nepojačani atazanavir može se nastaviti primjenjivati u bolesnika s blagim oštećenjem jetre u dozi od 400 mg, a u bolesnika s umjerenim oštećenjem funkcije jetre doza se mora smanjiti na 300 mg jedanput na dan i uzimati s hranom (vidjeti dio 5.2).
C-atazanavir, 79% and 13% of the total radioactivity was recovered in the faeces and urine, respectively.
C-atazanavira, 79% ukupne radioaktivnosti otkriveno je u stolici, a 13% u mokraći.
When atazanavir/ritonavir is co-administered with either phenytoin or phenobarbital, a dose adjustment of phenytoin or phenobarbital may be required.
Kada se atazanavir s ritonavirom primjenjuje istodobno s fenitoinom ili fenobarbitalom, možda će biti potrebna prilagodba doze fenitoina ili fenobarbitala.
In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
U bolesnika zaraženih HIV-om s teškom imunodeficijencijom u vrijeme početka kombinirane antiretrovirusne terapije (CART) može nastupiti upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
Particular caution should be used when prescribing Atazanavir Mylan in association with medicinal products which have the potential to increase the QT interval and/or in patients with pre-existing risk factors (bradycardia, long congenital QT, electrolyte imbalances (see sections 4.8 and 5.3).
Osobit se oprez treba primijeniti kad se Atazanavir Mylan propisuje zajedno s drugim lijekovima koji mogu produljiti QT interval i/ili u bolesnika s već prisutnim čimbenicima rizika (bradikardija, kongenitalno produljeni QT interval, poremećaji elektrolita) (vidjeti dijelove 4.8 i 5.3).
Select substitutions include any change at positions L10, K20, L24, V32, L33, M36, M46, G48, I50, I54, L63, A71, G73, V82, I84, and L90 (0-2, 3, 4 or more) at baseline.
Odabrane supstitucije uključuju svaku promjenu na položajima: L10, K20, L24, V32, L33, M36, M46, G48, I50, I54, L63, A71, G73, V82, I84 i L90 (0-2, 3, 4 ili više) na početku.
common: headache; uncommon: peripheral neuropathy, syncope, amnesia, dizziness, somnolence, dysgeusia
često: glavobolja; manje često: periferna neuropatija, sinkopa, amnezija, omaglica, somnolencija, disgeuzija
Atazanavir exhibits anti- HIV-1 (including all clades tested) and anti-HIV-2 activity in cell culture.
Atazanavir u staničnoj kulturi ima anti-HIV-1 (uključujući sve ispitane skupine) i anti-HIV-2 djelovanje.
Rashes are usually mild-to-moderate maculopapular skin eruptions that occur within the first 3 weeks of starting therapy with atazanavir.
Osipi su obično blage do umjerene makulopapularne erupcije koje nastaju tijekom prva 3 tjedna od početka terapije atazanavirom.
In a nonclinical fertility and early embryonic development study in rats, atazanavir altered oestrus cycling with no effects on mating or fertility (see section 5.3).
U nekliničkim ispitivanjima utjecaja na plodnost i rani embrionalni razvoj u štakora, atazanavir je promijenio ciklus estrusa bez učinaka na parenje ili plodnost (vidjeti dio 5.3).
Co-administration of atazanavir/ritonavir with boceprevir resulted in lower exposure of atazanavir which may be associated with lower efficacy and loss of HIV control.
Istovremena primjena kombinacije atazanavir/ritonavir s boceprevirom rezultirala je manjom izloženošću atazanaviru, što može biti povezano s manjom djelotvornošću i gubitkom kontrole HIV-a.
• interstitial nephritis (kidney inflammation), haematuria (blood in the urine), proteinuria (excess protein in the urine), pollakiuria (increased frequency of urination)
• intersticijalni nefritis (upala bubrega), hematurija (krv u mokraći), proteinurija (višak proteina u mokraći), polakizurija (učestalo mokrenje)
Clarithromycin AUC ↑94% (↑75%
Klaritromicin AUC ↑94% (↑75%
ANTIPSYCHOTICS Quetiapine
ANTIPSIHOTICI Kvetiapin
The choice of Atazanavir Mylan in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient's treatment history (see sections 4.4 and 5.1).
Odabir lijeka Atazanavir Mylan u prethodno liječenih odraslih i pedijatrijskih bolesnika treba biti utemeljen na pojedinačnom testiranju virusne rezistencije i prethodnom liječenju pojedinog bolesnika (vidjeti dijelove 4.4 i 5.1).
Other side effects reported for patients treated with atazanavir are the following:
Druge nuspojave prijavljene u bolesnika liječenih atazanavirom:
HORMONAL CONTRACEPTIVES Ethinyloestradiol 25 μg + norgestimate
Etinilestradiol 25 μg + norgestimat
Atazanavir has been evaluated for safety in combination therapy with other antiretroviral medicinal products in controlled clinical trials in 1,806 adult patients receiving atazanavir 400 mg once daily (1,151 patients, 52 weeks median duration and 152 weeks maximum duration) or atazanavir 300 mg with ritonavir 100 mg once daily (655 patients, 96°weeks median duration and 108 weeks maximum duration).
Sigurnost atazanavira procijenjena je u kombiniranoj terapiji s drugim antiretrovirusnim lijekovima u kontroliranim kliničkim ispitivanjima u 1806 odraslih bolesnika koji su primali atazanavir 400 mg jedanput na dan (1151 bolesnika, medijan trajanja liječenja 52 tjedna i maksimalno trajanje liječenja 152 tjedna) ili atazanavir 300 mg s ritonavirom 100 mg jedanput na dan (655 bolesnika, medijan trajanja liječenja 96 tjedana i maksimalno trajanje liječenja 108 tjedana).
Atazanavir (am): 2 hr after omeprazole
Atazanavir (am): 2 sata nakon omeprazola
100 to <200 cells/mm
100 do <200 stanica /mm
For co-administration of sildenafil for the treatment of erectile dysfunction see sections 4.4 and 4.5.
Za istovremenu primjenu sildenafila zbog liječenja erektilne disfunkcije, vidjeti dijelove 4.4 i 4.5.
Consistent results were obtained with the last observation carried forward method of analysis.
Metodom analize u kojoj se koristi prijenos posljednjih zabilježenih rezultata dobiveni su dosljedni rezultati.
In the majority of patients, a reduction in both voriconazole and atazanavir exposures are expected.
U većine bolesnika očekuje se smanjena izloženost kako vorikonazolu tako i atazanaviru.
Atazanavir Cmin ↓20% (↓31% ↓8%) In Healthy volunteers with atazanavir/ritonavir at an increased dose of 400/100 mg once daily
Atazanavir Cmin ↓20% (↓31% ↓8%) Primjena atazanavira/ritonavira u povišenoj dozi od 400/100 mg jedanput na dan u zdravih dobrovoljaca
There is no specific antidote for overdose with atazanavir.
Ne postoji posebni antidot za predoziranje atazanavirom.
uncommon: torsades de pointes a rare: QTc prolongation a, oedema, palpitation
manje često: torsades de pointes a rijetko: produljenje QTc intervala a, edem, palpitacije
In clinical trials of antiretroviral treatment naive patients treated with unboosted atazanavir, the I50L substitution, sometimes in combination with an A71V change, is the signature resistance substitution for atazanavir.
U kliničkim ispitivanjima antiretrovirusnog liječenja nepojačanim atazanavirom u bolesnika koji prethodno nisu bili liječeni, supstitucija I50L, ponekad u kombinaciji s promjenom na A71V, tipična je za rezistenciju na atazanavir.
Atazanavir (am): 1 hr after omeprazole
Atazanavir (am): 1 sat nakon omeprazola